MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
20.90
+0.06
+0.29%
Opening 15:23 12/05 EST
OPEN
20.52
PREV CLOSE
20.84
HIGH
20.98
LOW
20.23
VOLUME
408.38K
TURNOVER
0
52 WEEK HIGH
59.99
52 WEEK LOW
16.52
MARKET CAP
1.25B
P/E (TTM)
-1.9032
1D
5D
1M
3M
1Y
5Y
'Company Statement: Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor' - Sage Therapeutics
Benzinga · 13h ago
Weekly Report: what happened at SAGE last week (1127-1201)?
Weekly Report · 1d ago
Sage Therapeutic: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Biogen: LAQEMBI's $10 Billion Potential
Biogen's latest alzheimer's drug, aduhelm, faced challenges after fda approval. The company's latest drug, a new type of alzheimer's treatment, has raised concerns. Biogen has a $10 billion potential, according to main street investor's analysis of the stock.
Seeking Alpha · 6d ago
Weekly Report: what happened at SAGE last week (1120-1124)?
Weekly Report · 11/27 10:28
Weekly Report: what happened at SAGE last week (1113-1117)?
Weekly Report · 11/20 10:26
Buy These Stocks; Members Of The Most Hated Tech Sector
Biotech stocks have been heavily impacted by rising interest rates and ftc-challenging acquisitions of biotechs. The equal-weight biotech etf (xbi) has shown signs of a rebound after a prolonged downtrend. Selecting specific biotech names with potential for negative news can be a good investment strategy.
Seeking Alpha · 11/20 05:24
Weekly Report: what happened at SAGE last week (1106-1110)?
Weekly Report · 11/13 10:22
More
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing brain health medicines. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous systems (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The Company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

Webull offers SAGE Therapeutics Inc stock information, including NASDAQ: SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.